Arthritis Innovation Corporation (AIC) is a clinical-stage pharmaceutical company addressing unmet needs in orthopedic surgery and arthritis management.   

A private company founded in 2013, AIC leverages a world-class product development team located in Toronto, Canada and Denver, Colorado, and a proprietary polymer drug delivery system (BEPO®) formulated with previously marketed drugs. 

AIC's first drug in clinical development brings sustained, local delivery of a well-known NSAID for the management of pain and inflammation after total knee replacement (TKR) surgery, as an alternative to narcotics or oral NSAIDs. 

Completed Phase 2 Study: Clinicaltrials.gov: NCT03541655.   For more information, click HERE.

Upcoming Phase 3 Safety Arm:  Clinicaltrials.gov: NCT04860635.  For more information, click HERE.